Peekskill, NY
News
COVID-19: Here's When Vaccine Rollout May Start For Kids Ages 5 To 11 COVID-19: Here's When Vaccine Rollout May Start For Kids Ages 5 To 11
Covid-19: Here's When Vaccine Rollout May Start For Kids Ages 5 To 11 The Pfizer COVID-19 vaccine could be available to children ages 5 and older late in the fall or early this winter, according to a company board member. Former Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb told CNBC that he believes the company's COVID vaccine will be approved for emergency use for children ages 5 to 11 sometime this fall or winter. Gottlieb told the news outlet that the application will likely be submitted to the FDA in October.  He said the FDA will likely take four-to-six weeks to review the application, so the emergency use authorization c…

SHARE

by Nicole Valinote
Massapequa, NY
News
COVID-19: FDA Aims To Give Final Approval To Pfizer Vaccine Next Month COVID-19: FDA Aims To Give Final Approval To Pfizer Vaccine Next Month
Covid-19: FDA Aims To Give Final Approval To Pfizer Vaccine Next Month The Food and Drug Administration (FDA) is expected to determine whether or not to give full approval of Pfizer’s COVID-19 vaccine as soon as next month. As the Delta variant rapidly rages through the country, causing spikes in new COVID-19 cases, the FDA is reportedly accelerating its timeline to fully approve the Pfizer vaccine, which was the first shot available. Currently, the Pfizer - as well as the Johnson & Johnson and Moderna - vaccines have been given emergency use authorization. Under the current timeline, the FDA hopes to have full approval by Labor Day (Monday, Sept. 6). It…

SHARE

by Zak Failla
North Salem, NY
News
Sunscreen Recall May Be Expanded Due To Cancer-Causing Chemical Sunscreen Recall May Be Expanded Due To Cancer-Causing Chemical
Sunscreen Recall May Be Expanded Due To Cancer-Causing Chemical A team of researchers is now asking the Food and Drug Administration to recall a number of sunscreen brands after finding that they may contain a cancer-causing chemical. This follows an earlier recall of five sunscreen brands. Earlier report: Five Sunscreens Recalled Due To Cancer-Causing Chemical The New York Post reported that a team of researchers led by Executive Director of Haereticus Environmental Laboratory Craig Downs, asked the FDA to recall sunscreens containing octocrylene. They said the ingredient could degrade to suspected carcinogen benzophenone. The NY Post s…

SHARE

by Nicole Valinote
Pelham, NY
News
COVID-19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose COVID-19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose
Covid-19: Studies Determine How Effective Moderna Vaccine Is Six Months After Second Dose The Moderna COVID-19 vaccine has proven to be largely effective six months after Americans receive a second dose, according to recent studies conducted by the pharmaceutical company. Moderna CEO Stéphane Bancel announced this week that the latest round of studies into the vaccine found that it maintains 93 percent of its efficacy six months after the second dose is administered. Bancel said that while the vaccine remains effective, it is important to recognize the threat of variants of the virus, specifically the more transmissible Delta variant, which has been rapidly spreading across the …

SHARE

by Zak Failla
Bronxville, NY
News
COVID-19: FDA To Announce J&J Vaccine Has Been Linked To Rare Disorder, Report Says COVID-19: FDA To Announce J&J Vaccine Has Been Linked To Rare Disorder, Report Says
Covid-19: FDA To Announce J&J Vaccine Has Been Linked To Rare Disorder, Report Says The Food and Drug Administration is reportedly getting ready to announce a warning that the Johnson & Johnson COVID-19 vaccine has been linked to a rare autoimmune disorder. The Washington Post reported on Monday, July 12, that the Centers for Disease Control and Prevention said about 100 reports of Guillain-Barré syndrome have been detected among people who have received the Johnson & Johnson vaccine in the United States.  More than 12.8 million doses of the Johnson & Johnson vaccine have been administered in the U.S., the CDC reported. The Mayo Clinic said…

SHARE

by Nicole Valinote
Massapequa, NY
News
COVID-19: Mixed Messaging About Booster Shots From CDC, Pfizer Causing Confusion COVID-19: Mixed Messaging About Booster Shots From CDC, Pfizer Causing Confusion
Covid-19: Mixed Messaging About Booster Shots From CDC, Pfizer Causing Confusion Pfizer has announced plans to submit data on a COVID-19 booster vaccine it is developing to regulatory agencies in the coming weeks.  However, the Centers for Disease Control and Prevention and the Food and Drug Administration are pushing back, saying booster vaccines are not needed at this time. Confused? You're not alone. On Thursday, July 8, Pfizer and European partner BioNTech said in a news release that the companies are working on a third vaccine dose to combat COVID-19 and its variants, including the Delta variant. The companies said they expect clinical studies will begin in A…

SHARE

by Nicole Valinote
Pleasantville, NY
News
COVID-19: There Could Be Some Long-Term Loss Of Brain Tissue From Virus, New Study Says COVID-19: There Could Be Some Long-Term Loss Of Brain Tissue From Virus, New Study Says
Covid-19: There Could Be Some Long-Term Loss Of Brain Tissue From Virus, New Study Says There could be some long-term loss of brain tissue from COVID-19 that would have some lingering consequences, according to a brand-new study. That loss of brain tissue may explain why COVID patients lost their sense of smell, according to the study, which was conducted in the United Kingdom. "They looked at people who had had MRI scans of their brains in the past three years and they looked at how many developed COVID and about 300 people, a little over 300 people developed COVID," said former Food and Drug Administration Director Dr. Scott Gottlieb on CBS-TV's "Face the Nation" on Sunday, …

SHARE

by Joe Lombardi
Harrison, NY
News
COVID-19: New US-Made Vaccine Has 90 Percent Efficiency Rate, Can Be Stored In Refrigerators COVID-19: New US-Made Vaccine Has 90 Percent Efficiency Rate, Can Be Stored In Refrigerators
Covid-19: New Us-made Vaccine Has 90 Percent Efficiency Rate, Can Be Stored In Refrigerators An American biotech company announced that it has concluded the latest phase of clinical trials for its COVID-19 vaccine, which has proven to be highly effective. Novavax announced on Monday, June 14 that its vaccine has an overall efficacy rate of 90.4 percent in a Phase 3 trial that took place across the United States and Mexico. The Novavax vaccine can be stored in standard refrigerators, making it easier to distribute. Additional analysis of the trial is ongoing, according to the company, and will be submitted to peer-reviewed journals for publication. 
The company said that the vacc…

SHARE

by Zak Failla
Pelham, NY
News
COVID-19: Delta Variant's Symptoms Different, More Dangerous Than Original Virus, Doctors Say COVID-19: Delta Variant's Symptoms Different, More Dangerous Than Original Virus, Doctors Say
Covid-19: Delta Variant's Symptoms Different, More Dangerous Than Original Virus, Doctors Say The Delta variant of COVID-19, by far the most contagious strain during the entire pandemic, has different and more dangerous symptoms than the original virus, doctors are now warning. The strain, first detected in India in December 2020, now makes up 90 percent of new cases in the United Kingdom and 10 percent of new cases in the United States. Doctors in China told state-run television that their patients who have the Delta strain, known as B.1.617.2, are becoming sicker and their conditions are worsening at a faster rate, according to The New York Times. Around 12 percent of Delta varia…

SHARE

by Joe Lombardi
Torrington, CT
News
COVID-19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17 COVID-19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17
Covid-19: Moderna Asks FDA To Approve Vaccines For Those Ages 12 To 17 Moderna has requested an emergency use authorization from the Food and Drug Administration (FDA) for its COVID-19 vaccine in adolescents between the ages of 12 and 17. The company announced that clinical trials have shown that the vaccine has a 93 percent efficacy rate among adolescents, and has been proven to be safe. If approved, it would be the second COVID-19 vaccine authorized for adolescents, joining the Pfizer-BioNTech vaccine, which was given the green light for use earlier this month. In their study, Moderna found no cases of COVID-19 in participants who received two doses of th…

SHARE

by Zak Failla
Pound Ridge, NY
News
Beech-Nut Recalls Brand Of Rice Cereal, Will Stop Making Product Due To High Arsenic Levels Beech-Nut Recalls Brand Of Rice Cereal, Will Stop Making Product Due To High Arsenic Levels
Beech-Nut Recalls Brand Of Rice Cereal, Will Stop Making Product Due To High Arsenic Levels A grain rice cereal is being recalled by Beech-Nut Nutrition due to the presence of inorganic arsenic in the product that could impact infants and children, forcing the company to stop producing it altogether. The Food and Drug Administration (FDA) announced that the company has issued a voluntary recall of one lot of Beech-Nut Stage 1, Single Grain Rice Cereal after tests of the product showed that it was above the guidance level for naturally occurring inorganic arsenic. According to the FDA, it “has recognized that trace elements such as these are widely present in the environment, inclu…

SHARE

by Zak Failla
Massapequa, NY
News
COVID-19: Pfizer Begins Vaccine Study On Younger Children COVID-19: Pfizer Begins Vaccine Study On Younger Children
Covid-19: Pfizer Begins Vaccine Study On Younger Children Pfizer is moving forward with new clinical tests on thousands of children under the age of 12 as they look to expand the authorization of its COVID-19 vaccine. The company announced on Tuesday, June 8 that it will enroll up to 4,500 children between the ages of 6 months and 12 years old in the United States, Finland, Poland, and Spain with the intention of getting emergency use authorization before school begins in the fall. Currently, the Pfizer vaccine has only been authorized for use in children 12 and older. According to Pfizer, it has selected a dose of 10 micrograms in children betw…

SHARE

by Zak Failla